Details of the Drug Combination

General Information of Drug Combination (ID: DCWEDHD)

Drug Combination Name
Dichlorphenamide Dihydroergotamine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Dichlorphenamide   DMH7IDQ Dihydroergotamine   DM5IKUF
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 12.21
Bliss Independence Score: 12.21
Loewe Additivity Score: 25.75
LHighest Single Agent (HSA) Score: 25.75

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Dichlorphenamide
Disease Entry ICD 11 Status REF
Chronic glaucoma 9C61.0Z Approved [2]
Dichlorphenamide Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Carbonic anhydrase I (CA-I) TTHQPL7 CAH1_HUMAN Modulator [5]
Carbonic anhydrase II (CA-II) TTANPDJ CAH2_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Indication(s) of Dihydroergotamine
Disease Entry ICD 11 Status REF
Cluster headache 8A81.0 Approved [3]
Migraine 8A80 Approved [4]
Migraine disorder N.A. Approved [3]
Dihydroergotamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [7]
------------------------------------------------------------------------------------
Dihydroergotamine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6807).
3 Dihydroergotamine FDA Label
4 Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
7 Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94.
8 CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.